JP2008526839A - １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用 - Google Patents

１１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用 Download PDF

Info

Publication number
JP2008526839A
JP2008526839A JP2007550327A JP2007550327A JP2008526839A JP 2008526839 A JP2008526839 A JP 2008526839A JP 2007550327 A JP2007550327 A JP 2007550327A JP 2007550327 A JP2007550327 A JP 2007550327A JP 2008526839 A JP2008526839 A JP 2008526839A
Authority
JP
Japan
Prior art keywords
disorder
composition
disorders
pharmaceutically acceptable
related disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007550327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526839A5 (es
Inventor
パトリシア・シー・デイヴィス
ジェフリー・エム・ゴールドスタイン
スコット・ダブルュー・グリム
レイモンド・エフ・サッコウ
ヘレン・アール・ウィンター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2008526839A publication Critical patent/JP2008526839A/ja
Publication of JP2008526839A5 publication Critical patent/JP2008526839A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
JP2007550327A 2005-01-07 2006-01-04 １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用 Pending JP2008526839A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64226205P 2005-01-07 2005-01-07
US73786405P 2005-11-18 2005-11-18
US73786505P 2005-11-18 2005-11-18
US73788705P 2005-11-18 2005-11-18
PCT/SE2006/000009 WO2006073360A1 (en) 2005-01-07 2006-01-04 NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f] [1,4] THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS

Publications (2)

Publication Number Publication Date
JP2008526839A true JP2008526839A (ja) 2008-07-24
JP2008526839A5 JP2008526839A5 (es) 2009-02-26

Family

ID=36647771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007550327A Pending JP2008526839A (ja) 2005-01-07 2006-01-04 １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用

Country Status (6)

Country Link
EP (1) EP1838325A1 (es)
JP (1) JP2008526839A (es)
AR (1) AR052191A1 (es)
TW (1) TW200640466A (es)
UY (1) UY29326A1 (es)
WO (1) WO2006073360A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090069292A1 (en) * 2005-11-18 2009-03-12 Astrazeneca Ab Liquid Formulations
ME01516B (me) 2008-06-20 2014-04-20 Astrazeneca Ab DERIVAT DIBENZOTIAZEPINA l NJEGOVA UPOTREBA
US8389716B2 (en) 2009-01-30 2013-03-05 F.I.S. Fabbrica Italiana Sintetici S.P.A. Process for the synthesis of quetiapine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
JPS638378A (ja) * 1986-03-27 1988-01-14 アイ・シ−・アイ・アメリカス・インコ−ポレイテツド ジベンゾチアゼピン化合物、その製造法、ならびに該化合物を含有する、抗精神作用および神経弛緩作用を有する製薬学的組成物
JP2006518324A (ja) * 2003-02-21 2006-08-10 ピーピージー・インダストリーズ・オハイオ・インコーポレイテッド 透過色ずれが減少されている着色ガラス組成物及び自動車用視野パネル
JP2007534656A (ja) * 2003-12-22 2007-11-29 アカディア ファーマシューティカルズ，インコーポレーテッド ムスカリンアゴニストとしてのアミノ置換ジアリール［ａ，ｄ］シクロヘプテン類似体および精神神経疾患の治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
SE0003126D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
JP2004518699A (ja) * 2001-02-06 2004-06-24 アストラゼネカ・アクチエボラーグ クエチアピンを用いた物質乱用の治療方法
EP1578428A4 (en) * 2002-10-18 2008-11-26 Massachusetts Mental Health In TREATMENT OF ALCOHOL OR DRUG ABUSE BY ANTAGONIZING ALPHA-A2 DRENERGEN RECEPTORS WITH SWITCHING DOPAMINE BLOCKING
CN1816339B (zh) * 2003-07-02 2010-12-15 阿斯利康(瑞典)有限公司 喹硫平的代谢物
WO2005053619A2 (en) * 2003-12-04 2005-06-16 The Research Foundation Of The City University Of New York Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
JPS638378A (ja) * 1986-03-27 1988-01-14 アイ・シ−・アイ・アメリカス・インコ−ポレイテツド ジベンゾチアゼピン化合物、その製造法、ならびに該化合物を含有する、抗精神作用および神経弛緩作用を有する製薬学的組成物
JP2006518324A (ja) * 2003-02-21 2006-08-10 ピーピージー・インダストリーズ・オハイオ・インコーポレイテッド 透過色ずれが減少されている着色ガラス組成物及び自動車用視野パネル
JP2007534656A (ja) * 2003-12-22 2007-11-29 アカディア ファーマシューティカルズ，インコーポレーテッド ムスカリンアゴニストとしてのアミノ置換ジアリール［ａ，ｄ］シクロヘプテン類似体および精神神経疾患の治療方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HASSELSTROM J ET AL, J CHROMATGR B, vol. 798, JPN6012011562, 2003, pages 9 - 16, ISSN: 0002163717 *
SATTAR SP ET AL, J PSYCHIATRY NEUROSCI, vol. 29, no. 6, JPN6012011563, 2004, pages 452 - 7, ISSN: 0002163718 *
最新創薬化学上巻, JPN6012011560, 2001, pages 96 - 103, ISSN: 0002163719 *

Also Published As

Publication number Publication date
TW200640466A (en) 2006-12-01
UY29326A1 (es) 2006-08-31
AR052191A1 (es) 2007-03-07
EP1838325A1 (en) 2007-10-03
WO2006073360A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
EP1644005B1 (en) Metabolite of quetiapine
JP2009516707A (ja) 固形製剤
US20110136786A1 (en) Method of treating mood disorders
US20110144089A1 (en) Method of treating schizophrenia and other disorders
JP2008526839A (ja) １１−ピペラジン−１−イルジベンゾ［ｂ，ｆ］［１，４］チアゼピン又はその薬学的に許容される塩の新規な使用及び経口医薬組成物への新規な使用
US20110136784A1 (en) Method of Treating Anxiety Disorders
CN101351210A (zh) 11－哌嗪－1－基二苯并[b,f][l,4]硫氮杂卓或其药学上可接受的盐的新用途及其用于口服药物组合物的新用途
US20020025956A1 (en) 1-azatricyclic-4-benzylpiperazines
WO2018139471A1 (ja) ジベンゾジアゼピン誘導体
US20100022510A1 (en) Crystalline Forms
US20110136785A1 (en) Method of treatment
US8389510B2 (en) Crystalline forms
US20090093460A1 (en) Compositions
JP2009516708A (ja) 液体製剤
US20100093700A1 (en) Methods of Treating Mood Disorders
US20060252743A1 (en) Method of treating sleep disorders
US20090093461A1 (en) Methods of Treating Anxiety and Mood Disorders
WO2007062336A2 (en) Salt forms
US20060229292A1 (en) Method of treating childhood disorders
ITRM20000432A1 (it) Pirrolo [2,1-b] [1,3] benzotiazepine e loro uso per la preparazione di medicamenti ad attivita' antipsicotica classica.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120807